For active psoriatic arthritis (PsA) in adult TNFi‑IR patients1
Abbvie's
commitment to
exceptional
access and patient
support
Get started with the Enrollment & Prescription Form
Get started with the Enrollment & Prescription Form
99% Preferred
National Commercial Coverage
Payers cover RINVOQ after the trial of 1 TNFi, with 99% of patients
having preferred coverage.2
Preferred coverage also could
mean a STANDARD PRIOR
AUTHORIZATION (PA) and
APPEALS PROCESS,
potential for one-time
PA/appeal approval.
*Formulary Definitions: Preferred means RINVOQ is placed on the plan’s preferred formulary. Based on formulary status under the pharmacy benefit.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
JAKi=Janus kinase inhibitor; PsA=psoriatic arthritis; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor
Commercial plan preferred formulary status for 2L TIM therapies for active PsA under the pharmacy benefit in 20222
Most national and regional health plans may not approve non-preferred products for patients who have shown clinical stability solely through the use of samples or other free goods.
The products listed here are not interchangeable and are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, clinical safety, and line of therapy.
No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, product safety profile, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.
Please see HUMIRA full Prescribing Information.
Look up commercial insurance plans for RINVOQ in your area
- Plane Name
- Plan Type
Increasing
Medicare PART D coverage to
RINVOQ® (upadacitinib) FOR APPROPRIATE PATIENTS2
*Formulary Definitions: Preferred means RINVOQ is placed on the plan’s preferred formulary. Based on formulary status under the pharmacy benefit.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.
JAKi=Janus kinase inhibitor; PsA=psoriatic arthritis; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor
Medicare Part D plan preferred formulary status for 2L TIM therapies for active PsA under the pharmacy benefit in 20222
The products here are not interchangeable and are not pharmaceutically equivalent or bioequivalent. They differ with respect to active and inactive ingredients, strength, dosage, indications, clinical efficacy, safety, and line of therapy.
No conclusions regarding comparative safety or efficacy can be drawn from this information. Selection of a treatment regimen should be individualized for each patient based on factors including, but not limited to, product efficacy, adverse events, dosage and administration, potential for drug interactions, patients’ test results, and comorbid conditions.
Please see HUMIRA full Prescribing Information.
ENCOURAGE YOUR
PATIENTS TO ENROLL IN
*Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
†Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
Two products.
One exceptional patient experience.
Nurse
Ambassadors*
Empower patients
Our Nurse Ambassadors are the heart of RINVOQ Complete and HUMIRA Complete
Nurse Ambassadors provide 1:1 support to help patients start and stay on track with their prescribed treatment plan, including:
- Help patients understand the importance of following the treatment plan prescribed by their healthcare professional.
- Committed to answering questions throughout the experience to help limit treatment disruptions.
- Answer patients’ insurance questions and connect them with additional insurance expertise.
- Identify ways for patients to save on prescription costs.
Access
SPECIALISTS
Insurance support when needed
- Resource with expertise on Medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient’s unique financial situation.
- Can educate on payer prior authorization and appeal processes so you can determine the best access option for each patient’s unique situation.
ACCESS & SAVINGS
Help with access & treatment affordability
COMPLETE can help your commercial patients save:
- With the Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per month.†
- Complete may help eligible commercially insured patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established.‡
Empowering Patients
Nurse Ambassadors, In Their Own Words
Have questions or need support over the phone?
Call 1-877-COMPLETE
(1-800-274-6867)
*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.
†Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) or HUMIRA® (adalimumab) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com for RINVOQ patients, and HUMIRASavingsCard.com for HUMIRA patients. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
‡Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
HOW TO ENROLL PATIENTS IN
RINVOQ COMPLETE
Help patients get the support they need to start and stay
on track with their prescribed treatment
To enroll a patient in RINVOQ Complete:
Download the enrollment & prescription form for your specialty
Fill out the form with your patient
- This form enrolls your patient and can be used to initiate a prescription with your patient’s preferred specialty pharmacy.
- The RINVOQ Complete Prescription section may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*
Fax the form to 1-678-727-0690
- You will receive a call from an Access Specialist to discuss next steps.
- If using the Pharmacy Prescription section, fax a copy to your patient’s specialty pharmacy as well.
Inform your patient that they have been enrolled
- Let your patient know to expect a call from their Nurse Ambassador.†
*Commercial insurance coverage varies by type and plan. Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
†Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.
COMPLETE APP
Track treatment
The Complete App is designed to help patients stay on track with their prescribed RINVOQ or HUMIRA treatment by helping them:
- Access additional resources, including a savings card for those that are eligible
- Set customized medication reminders
- Log symptoms
- Log medication lot number and medication expiration date
COMPLETEPRO.COM
Streamline the Rx process
CompletePro.com enables seamless enrollment into RINVOQ Complete and HUMIRA Complete, and helps streamline the prescription process for your patients.
With CompletePro.com, you can:
- Request benefits verifications
- Complete and submit prior authorizations
- Send prescriptions to the patient’s specialty pharmacy of choice, with the option to include a savings card
- Receive alerts for annual reauthorizations and renewals
- Track and monitor where patients are in the prescription process
Learn more about streamlining the prescription process with Complete Pro:
Register now at
Downloadable Resources
Download RINVOQ resources to support your
patients and your practice.
RINVOQ SAFETY DATA
Review the safety profile of RINVOQ,
including both short- and long-term analyses
